Middle East & Africa Blood Cancer Diagnostics Market Size & Outlook
The blood cancer diagnostics market in Middle East & Africa is expected to reach a projected revenue of US$ 552.4 million by 2030. A compound annual growth rate of 4.8% is expected of Middle East & Africa blood cancer diagnostics market from 2025 to 2030.
The MEA blood cancer diagnostics market generated a revenue of USD 417.9 million in 2024.
The market is expected to grow at a CAGR of 4.8% from 2025 to 2030.
In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
Market revenue in 2024
USD 417.9 million
Market revenue in 2030
USD 552.4 million
Growth rate
4.8% (CAGR from 2025 to 2030)
Largest segment
Assay kits and reagents
Fastest growing segment
Assay Kits and Reagents
Historical data covered
2018 - 2023
Base year for estimation
2024
Forecast period covered
2025 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Instruments, Assay Kits and Reagents
Other key industry trends
In terms of revenue, MEA region accounted for 3.9% of the global blood cancer diagnostics market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 4,265.2 million by 2030.
MEA countries are increasingly adopting molecular and genetic testing into their diagnostic protocols. These technologies allow more precise classification of hematologic malignancies, aiding in treatment decision-making and prognostication. The adoption of these advanced techniques, however, varies across the region, influenced by factors such as the availability of infrastructure, skilled healthcare professionals, and financial resources.
Moreover, the increasing number of clinical trials and research initiatives is driving innovation in blood cancer diagnostics within the MEA region. Academic institutions, research centers, and pharmaceutical companies are conducting clinical trials to evaluate novel diagnostic technologies, biomarkers, and therapeutic interventions for hematologic malignancies.
Participation in international collaborative research networks and initiatives such as the Global Initiative for Cancer Registry Development (GICR) & the African Cancer Registry Network (AFCRN) are also expanding research opportunities and advancing knowledge in blood cancer diagnostics specific to MEA population.
Middle East & Africa Blood Cancer Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Blood Cancer Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Assay Kits And Reagents was the largest segment with a revenue share of 73.15% in 2024.
Horizon Databook has segmented the Middle East & Africa blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.
MEA countries are increasingly adopting molecular and genetic testing into their diagnostic protocols. These technologies allow more precise classification of hematologic malignancies, aiding in treatment decision-making and prognostication. The adoption of these advanced techniques, however, varies across the region, influenced by factors such as the availability of infrastructure, skilled healthcare professionals, and financial resources.
Moreover, the increasing number of clinical trials and research initiatives is driving innovation in blood cancer diagnostics within the MEA region. Academic institutions, research centers, and pharmaceutical companies are conducting clinical trials to evaluate novel diagnostic technologies, biomarkers, and therapeutic interventions for hematologic malignancies.
Participation in international collaborative research networks and initiatives such as the Global Initiative for Cancer Registry Development (GICR) & the African Cancer Registry Network (AFCRN) are also expanding research opportunities and advancing knowledge in blood cancer diagnostics specific to MEA population.
Middle East & Africa Blood Cancer Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
Instruments
Assay Kits and Reagents
Middle East & Africa Blood Cancer Diagnostics Market Test Outlook (Revenue, USD Million , 2018-2030)
Blood Tests
Imaging Tests
Biopsy
Molecular Test
Middle East & Africa Blood Cancer Diagnostics Market Enduse Outlook (Revenue, USD Million , 2018-2030)
Hospitals and Clinics
Diagnostic Labs
Research Institutes
Reasons to subscribe to Blood Cancer Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Blood Cancer Diagnostics Market Outlook databook
Our clientele includes a mix of Blood Cancer Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Blood Cancer Diagnostics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Blood Cancer Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Middle East Africa Blood Cancer Diagnostics Market, 2018-2030 (US$M)